Axillary lymph node dissection in breast cancer - Current status and controversies, alternative strategies and future perspectives

Acta Oncologica

Volumn 39, Issue 4, 2000, Pages 455-466

  Sakorafas, George H ^a,b   Tsiotou, Adelais G ^a   Balsiger, Bruno M ^a  

^a IASO GENERAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CONTROL; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MEDICAL DECISION MAKING; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033804976     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418600750013366     Document Type: Review

References (137)

1. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation
2. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer
3. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer
4. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute Trials
5. Randomized clinical trial to assess the value of breast-conserving therapy in stage I and II breast cancer: EORTC 10801 trial
6. Danish randomised trial comparing breast conservation therapy with mastectomy: Six years of life-table analysis
7. Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group
8. Effects of radiotherapy and surgery in early breast cancer
9. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. One hundred and thirty-three randomized trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
10. Adjuvant chemotherapy in the node-negative breast cancer patient
11. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer
12. Axillary lymph node dissection: Does it have a role in primary breast cancer?
13. Axillary dissection: An obsolete operation?
14. Integumental system: Skin and breasts
15. Lymph node metastases in carcinoma of the female mammary gland
16. The significance of axillary node levels in the study of breast carcinoma
17. Extent of metastatis axillary involvement in 1 446 cases of breast cancer
18. Clinical evaluation of axillar lymph nodes compared to surgical and pathological findings
19. Clinical and biological prediction of axillary and internal mammary lymph node metastases in breast cancer
20. Diagnosis of axillary lymph node metastases in patients with breast cancer
21. Real-time ultrasound, axillary mammography, and clinical examination in the detection of axillary lymph node metastases in breast cancer patients
22. Modern thoughts on lymph nodes in breast cancer
23. Ultrasonographic detection of metastatic axillary lymph nodes in breast cancer
24. Ultrasound detection of axillary lymph node metastases in breast cancer
25. Colour Doppler studies of axillary node metastases in breast carcinoma
26. Needleman L. CT-pathologic correlation of axillary lymph nodes in breast carcinoma
27. Prospects for axillary staging in breast cancer by magnetic resonance imaging
28. Detection of axillary lymph node metastasis of breast carcinoma with technitium-99m sestamibi scintimammography
29. Nuclear approaches for detection of axillary lymph node metastases
30. Staging of the axilla in breast cancer. Accurate in vivo assessment using positron emission tomography with 2-(Fluorine-18)-Fluoro-2-Deoxo-D-glucose
31. Standards for diagnosis and management of invasive breast carcinoma
32. Distribution of axillary node metastases by level of invasion: An analysis of 539 cases
33. Patterns of axillary metastases in breast cancer
34. Patterns of axillary nodal involvement in breast cancer: Predictability of level one dissection
35. The correlation between the spread of metastases by level in the axillary nodes and disease-free survival in breast cancer: A multifactorial analysis
36. Patterns of axillary lymph node metastasis in breast cancer
37. Total axillary lymphadenectomy in the management of breast cancer
38. Axillary lymph nodes and breast cancer
39. Prospective evaluation of clinical and pathologic detection of axillary metastases in patients with carcinoma of the breast
40. A mathematical model of axillary lymph node involvement based on 1 446 complete axillary dissections in patients with breast carcinoma
41. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma
42. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?
43. Predictors of axillary lymph node metastases in patients with T1 breast cancer. A multivariate analysis
44. Prediction of axillary lymph node metastases in a screening breast cancer population. South-East Sweden Breast Cancer Group
45. Axillary node metastasis from T1N0M0 breast cancer: Possible avoidance of dissection in a subgroup
46. Axillary lymph node dissection for breast cancer: A decision analysis of T1 lesions
47. Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma
48. Axillary lymph node dissection: Is it required in T1a breast cancer?
49. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases
50. The value of axillary dissection in T1a breast cancer
51. A cost-effectiveness analysis of axillary lymph node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes
52. Recurrence-free survival in patients with small breast cancers
53. Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability
54. Management of the axilla in patients with breast cancers one centimeter or smaller
55. Nonpalpable invasive breast cancer
56. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation: Correlation of pathologic parameters with outcome of treatment
57. Axillary lymphadenectomy for intraductal carcinoma of the breast
58. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation
59. Prognosis and treatment in minimal breast cancer
60. Intraductal carcinoma. Analysis of presentation, pathologic findings, and outcome of disease
61. Breast carcinoma in situ
62. Treatment of pure tubular carcinoma of the breast
63. Axillary dissection for tubular carcinoma of the breast
64. Tubular carcinoma of the breast: Mode of presentation, mammographic appearance, and frequency of nodal metastases
65. Predicting axillary lymph node metastases in breast carcinoma patients
66. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: A multivariate analysis
67. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer
68. Correlation of DNA flow cytometry and hormone receptors with axillary lymph node status in patients with carcinoma of the breast
69. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators
70. The impact of histopathology on nodal metastases in minimal breast cancer
71. The role of axillary dissection in mammographically detected carcinoma
72. Flow cytometry in breast cancer: Prognostic and surgical indications of the sparing of axillary lymph node dissection
73. Lymph node metastasis in breast cancer: Common prognostic markers lack predictive value
74. The Nottingham Prognostic Index applied to 9 149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG)
75. Axillary lymph node dissection of level I and II lymph nodes is important in breast cancer classification: The Danish Breast Cancer Cooperative Group (DBCG)
76. Regional nodal failure after conservative surgery and radiotherapy for early stage breast carcinoma
77. Regional nodal irradiation in the conservative treatment of breast cancer
78. Value of axillary lymph node dissection in addition to lumpectomy and radio-therapy in early breast cancer
79. Breast cancer adjuvant therapy
80. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors
81. Efficacy of adjuvant chemotherapy in high risk node-negative breast cancer: An intergroup study
82. NIH Consensus Conference. Treatment of early-stage breast cancer
83. Surgical and medical management of in situ and early stage breast carcinoma
84. Are positive axillary lymph nodes in breast cancer markers for incurable disease?
85. Patients with early breast cancer benefit from effective axillary treatment
86. The impact of prophylactic axillary node dissection on breast cancer survival - A Bayesian meta-analysis
87. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 92b Trial
88. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial
89. Complications of axillary lymph node dissection for carcinoma of the breast: A report based on a patient survey
90. Quality of life of breast cancer patients with lymphedema
91. Assessment of morbidity from complete axillary dissection
92. Impact of axillary lymph node dissection on the therapy of breast cancer patients
93. Arm function after axillary dissection for breast cancer: A pilot study to provide parameter estimates
94. The Guy's trial of treatment of 'early' breast cancer
95. Alternative strategies in the management of primary breast cancer
96. Local management of invasive breast cancer
97. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer
98. Long-term outcome in patients with four or more positive lymph nodes treated with conservative surgery and radiation therapy
99. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast
100. Conservation surgery after primary chemotherapy in large carcinomas of the breast
101. Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer
102. Effect of preoperative chemotherapy on locoregional disease in women with operable breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-18
103. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer
104. A study of results - Johns Hopkins Hospital, 1889-1931
105. Selection criteria for breast-conserving surgery
106. Age does not predict breast cancer outcome
107. Treatment of carcinoma of the breast in the older geriatric patient
108. Breast disease in elderly women
109. Tamoxifen as an alternative to surgical resection for selected patients with primary breast cancer
110. CRC (Kings/Cambridge) trial for early breast cancer: A detailed update at the tenth year
111. Clinical behavior of untreated axillary nodes after local treatment for primary breast cancer
112. Outcome in breast cancer managed without an initial axillary lymph node dissection
113. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: Influence of axillary dissection for treatment of T1a and T1b lesions
114. Simple mastectomy for early breast cancer and the behavior of untreated axillary nodes
115. Treatment of the axilla in operable breast cancer
116. The role of axillary dissection in operable breast cancer
117. Level I and II axillary dissection in the treatment of early stage breast cancer: An analysis of 259 consecutive patients
118. The effect of surgical technique on local recurrence rates following mastectomy
119. Conservation treatment of early breast cancer: Long-term results and complications
120. Breast cancer: Risk of axillary recurrence in node-negative patients following partial resection of the axilla
121. South-east Scottish trial of local therapy in node negative breast cancer
122. The Cardiff local therapy trial-results at 20 years
123. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer
124. The importance of surgery and accurate axillary staging for survival in breast cancer
125. Breast conservation therapy without axillary dissection. A rational treatment strategy in selected patients
126. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection
127. Optimal management of primary breast cancer
128. Breast cancer in women over 75 years: Is axillary dissection always necessary?
129. Sentinel lymph node biopsy in breast cancer; technique, limitations, and future perspectives
130. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary lymph node dissection?
131. Meeting highlights: International consensus panel on the treatment of primary breast cancer
132. Axillary lymphadenectomy by lipo-aspiration and endoscopic picking. A propos of 72 cases
133. Endoscopic exploration and lymph node sampling of the axilla. Preliminary findings of a randomized pilot study comparing clinical and anatomo-pathologic results of endoscopic axillary lymph node sampling with traditional surgical treatment
134. Endoscopic axillary exploration and sentinel lymphadenectomy
135. Endoscopic axilla dissection in invasive breast carcinoma. Initial experience with a new technique